ClinicalTrials.gg
Active, not recruitingNCT05230550Updated Apr 13, 2026

Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®

An observational study in Adult Growth Hormone Deficiency, sponsored by Novo Nordisk A/S. Active, not recruiting at 47 sites in Japan. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Novo Nordisk A/S · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies in Dwarfism, Pituitary by Novo Nordisk A/S — 2 open to participants now, 3 under way, none of them phase 3. Dwarfism, Pituitary · Novo Nordisk A/S.

Planned enrollment
8th of 10
200 · median 394
Started
2022
the only one that year
Observational
10 of 27
2 open now
Registered
25th of 27
by date

Among the 27 studies in Dwarfism, Pituitary by Novo Nordisk A/S, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2022, is one of 10 observational ones, and was the 25th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

2 of the 27 studies in Dwarfism, Pituitary by Novo Nordisk A/S are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Dwarfism, Pituitary by Novo Nordisk A/S, or all of them as a file.
02

Study summary

Participants are invited to take part in this study because they have AGHD (only severe case). The purpose of this study is to assess long term safety and effectiveness of Sogroya® in patients with AGHD (only severe case) under normal clinical practice condition in Japan. Participants will get Sogroya® as prescribed by the study doctor. Participants will be in the study for about 2 to 5 years depending on when they take part in the study. Participants will be asked to fill in the quality of life questionnaires.

03

Conditions studied

  • Adult Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with Adult Growth Hormone Deficiency (only severe case)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
  2. The decision to initiate treatment with commercially available Sogroya® has been made by the patient/LAR and the treating physician before and independently from the decision to include the patient in this study.
  3. Male or female, no age limitation
  4. Diagnosis of AGHD (only severe case)
  5. GH treatment naïve ("naïve patients") or "switched patients". "Naïve patients" are patients who are not exposed to any GH product to date or patients who were exposed to other GH product more than 180 days prior to registration. "Switched patients" are patients who is now treated by other GH product or patients who were exposed to other GH product within 180 days prior to registration.

Exclusion criteria

Exclusion Criteria:

  1. Previous participation in this study. Participation is defined as having given in this study
  2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  3. Patients with to the active substance or to any of the
  4. Patients with malignant tumor
  5. Female patients who are either pregnant or likely to be pregnant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants with AGHD (only severe case)

    Participants will be treated with commercially available Sogroya® according to routine clinical practice at the discretion of the treating physician. The decision to treat a patient with Sogroya® has been made at the treating physician's discretion and independently from the decision to include the patient in this study.

    Drug: Somapacitan

Interventions

  • Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions

    Also known as: Sogroya®

06

What researchers measure

Primary outcomes

  1. Number of adverse events

    Measured as number

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  2. Number of serious adverse events

    Measured as number

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  3. Number of serious adverse reactions

    Measured as number

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  4. Number of adverse reactions

    Measured as number

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

Secondary outcomes

  1. Change in body fat mass

    Measured as kilogram (kg)

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  2. Change in body fat percentage

    Measured as percent (%)

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  3. Change in lean body mass

    Measured as kg

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  4. Change in cross-sectional total adipose tissue compartments (TAT)

    Measured as square centimeter (cm\^2)

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  5. Change in subcutaneous adipose tissue compartments (SAT)

    Measured as cm\^2

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  6. Change in visceral adipose tissue compartments (VAT)

    Measured as cm\^2

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  7. Change in Total cholesterol (T-Cho)

    Measured as milligrams per deciliter (mg/dL)

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  8. Change in Low Density Lipoprotein-Cholesterol (LDL-Cho)

    Measured as mg/dL

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  9. Change in High Density Lipoprotein-Cholesterol (HDL-Cho)

    Measured as mg/dL

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  10. Change in triglyceride

    Measured as mg/dL

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  11. Change in Insulin-like Growth Factor I (IGF-I) standard deviation score (SDS)

    Measured as standard deviation score

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  12. Change in Quality of Life (QOL) Adult Hypopituitarism Questionnaire (AHQ) score

    Measured as score range (0 = unfavorable to 6 = favorable)

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

  13. Change in QOL Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD) score

    Measured as score range (1 to 5; lower score indicates a better health state)

    Time frame: From baseline (week 0) to end of study (up to 260 weeks)

07

Study locations

47 sites
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Dec 2026, 58 months after the start.

Of 30 observational studies under Dwarfism, Pituitary, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 102. This study's planned 58 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2022
First posted
Feb 9, 2022
StartActual
Feb 3, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05230550
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 9, 2022
Start date
Feb 3, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion